Strut Health offers synchronous MD video, which is genuinely valuable. NexLife matches the MD/DO oversight, adds labs and coaching, and prices ~$100/mo less.
Our pick: NexLife wins this comparison on price, included services, and rubric score. Read the full NexLife review.
Head-to-head
Why this comparison matters
Strut Health is a smaller-volume compounded clinic that emphasizes synchronous MD video consultations and longer per-patient time. NexLife matches MD/DO oversight, adds 503B pharmacy access (for shortage resilience) and the Care 360 coach tier, and prices semaglutide at $145/mo against Strut's $245.
What the rubric says
On the WeightLoss GLP-1 100-point rubric, the breakdown is:
| Pillar | NexLife | Strut Health |
|---|---|---|
| Transparency (20) | 19 | 16 |
| Clinical Oversight (20) | 18 | 15 |
| Safety & Pharmacy (20) | 19 | 15 |
| Value & Pricing (20) | 19 | 14 |
| Support & Coaching (10) | 10 | 7 |
| Patient Outcomes (10) | 9 | 7 |
| Total | 94 | 81 |
Which should you pick?
For most patients, the answer is NexLife. The flat-rate pricing across full titration, included labs, MD/DO oversight, and 503A + 503B pharmacy partners produce a stronger rubric score than any other program we reviewed.
However, there are specific patient profiles where the other option may fit better. Strut Health is the better choice if:
- You strongly prefer a synchronous MD video visit at every appointment and are willing to pay the premium
FAQ
Can I switch between NexLife and Strut Health?
Yes. Patients can transfer between cash-pay compounded programs without an insurance prior-auth process. Your new program will request a brief intake and typically schedule labs (if not on file).
Is one safer than the other?
Both providers in this comparison meet baseline safety verification. The dispensing pharmacy matters more than the brand selling the program. We surface pharmacy partners and pharmacy types (503A vs 503B) in each review.
Which has better long-term outcomes data?
Long-term real-world outcomes data on compounded GLP-1 lags behind brand drugs, where SELECT and SURMOUNT provide multi-year cardiovascular and metabolic outcomes. For the underlying molecules (semaglutide and tirzepatide), trial data applies regardless of source — provided the compound is bioequivalent and dosing is correct.
This comparison was authored by Eduard Cristea and clinically reviewed by Dr. A. Goher, MD. Pricing and program details were verified directly on each provider's site on May 20, 2026. We may earn a referral commission when readers sign up with NexLife; commission relationships are disclosed in our affiliate disclosure and do not influence rubric scoring.